期刊文献+

Ⅰ~Ⅲ期结直肠癌淋巴结转移比率与预后关系 被引量:6

Retrospective analysis of the relationship between metastatic lymph node ratio and survival in stage Ⅰ~Ⅲ colorectal cancer
原文传递
导出
摘要 目的评价Ⅰ~Ⅲ期结直肠癌淋巴结转移比率与患者预后的关系。方法回顾性分析中山大学附属第一医院胃肠胰腺外科2004年6月至2008年11月间446例行根治性切除的结直肠癌患者临床病理数据,探讨结直肠癌预后相关危险因素,评估结直肠癌淋巴结转移比率与患者预后的关系。结果 446例结直肠癌Ⅰ、Ⅱ、Ⅲ期患者的5年总体生存率分别约为87.4%,83.1%和64.8%(Log-rank检验,P<0.001)。我们根据淋巴结转移比率(metastatic lymph node ratio,mLNR)将CRC患者分为三组:A组:mLNR为0;B组:m LNR为>0%~14%;C组:mLNR为>14%。A、B、C组三组患者的5年总体生存率分别约为84.3%、79.6%和49.1%(Log-rank检验,χ2=55.959,P<0.001)。就直肠癌患者而言,A、B、C三组5年生存率分别为79.0%、73.5%和43.2%(Log-rank检验,χ~2=26.332,P<0.001)。而对于结肠癌患者来说三组的5年生存率分别为87.1%,80.8%和55.5%(Log-rank检验,χ~2=21.214,P<0.001)。单因素和多因素Cox分析均显示,mLNR是结直肠癌独立的预后危险因素,随着m LNR的上升,结直肠癌患者的预后变差。结论淋巴结转移比率(mLNR)是结直肠癌患者预后的独立危险因素,与N分期类似,但更有优势,可作为评估结直肠癌患者预后的指标之一。 Objective To retrospectively investigate the relationship between metastaticlymph node ratio and prognosis in stage I^III colorectal cancer. Methods The clinicopathologic data of446 patients with stage I^III colorectal cancer treated with curative resection at gastrointestinopancreaticsurgery department of the First Affiliated Hospital of Sun Yat-sen University was retrospectively analyzed.Factors including metastatic lymph node ratio, pT stage, chemoradiotherapy, gender, age, histological grade,histological type and tumor size were univariate and multivariate analyzed to investigate the correlatedprognostic risk factors in colorectal cancer. Results Among the 446 colorectal cancer patients, the overall5-year survival rates in NCCN stage I, II, III were 87.4%, 83.1%, 64.8% separately (P < 0.001). For therectal cancer subgroup, the overall 5-year survival rates in NCCN stage I, II, III were 86.5%, 73.7%, 56.2%separately (P<0.001). And for the colon cancer subgroup, the rates were 83.7%, 86.4% and 70.9% separately(P < 0.001). When putting the patients into three groups according to the metastatic lymph node ratio(cutoffs 0, >0%~14%, >14%), we found an overall 5year survival rates of 81.8%, 77.7% and 57.2% separately(χ2=55.959, P < 0.001) for the whole CRC patients. And the rates were 79.0%, 73.5% and 43.2% separately (χ2=26.332, P < 0.001) for the rectal cancer subgroup and 87.1%, 80.8 and 55.5% separately (χ2=21.214,P < 0.001) for the colon cancer subgroup. In univariate and multivariate analysis, metastatic lymph node ratio(mLNR) was found to be significantly associated with overall survival. The poor prognosis was associated withincreasing mLNR. In the rectal cancer subgroup and colon cancer subgroup, similar results were achieved.mLNR is an independent prognostic factors for colorectal cancer. Conclusions Metastatic lymph noderatio (mLNR) is an independent prognostic factor of colorectal cancer patients. The mLNR classification incolorectal cancer is similar with the pN stage classification, but more precise, in the prognostic assessment.
作者 吴建海 韩方海 陈进忠 Wu Jianhai;Han Fanghai;Chen Jinzhong(The Endoscopy Center, the First Affiliated Hospital of Xiamen University, Fujian 361000, China;The Department of Gastrointestinal Surgery,the Second Affiliated Hospital of Sun Yat-sen University, Guangdong 510120, China)
出处 《中华结直肠疾病电子杂志》 2016年第2期138-147,共10页 Chinese Journal of Colorectal Diseases(Electronic Edition)
关键词 结直肠肿瘤 预后 淋巴结转移比率 Colorectal neoplasms Prognosis Metastatic lymph node ratio
  • 相关文献

参考文献26

  • 1康清杰,向征.结肠癌筛查和诊疗的研究进展[J].重庆医学,2015,44(28):4001-4003. 被引量:47
  • 2Staib L, Link KH, Blatz A, et al. Surgery of colorectal cancer: surgicalmorbidity and five and ten-year results in 2400 patients--monoinstitutionalexperience. World J Surg. 2002; 26(1): 59-66.
  • 3Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer StagingManual. 5th ed. Philadelphia, PA: Lippincott, 1997.
  • 4Sobin LH, Wittekind C. TNM Classification of Malignant Tumors.5th ed. New York, NY: Wiley, 1997.
  • 5Thomas M, Biswas S, Mohamed F, et al. Dukes C colorectal cancer:is the metastatic lymph node ratio important?. Int J Colorectal Dis,2012, 27(3): 309-317.
  • 6Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of thelymph node ratio in stage III colorectal cancer: a systematic review.Ann Surg Oncol, 2010, 17(11): 2847-2855.
  • 7Parsons HM, Tuttle TM, Kuntz KM, et al. Association BetweenLymph Node Evaluation for Colon Cancer and Node Positivity Over the Past 20 Years. JAMA, 2011, 306(10): 1089-1097.
  • 8Powell AG, Wallace R, McKee RF, et al. The relationship betweentumour site, clinicopathological characteristics and cancer-specificsurvival in patients undergoing surgery for colorectal cancer.Colorectal Dis, 2012, 14(12): 1493-1499.
  • 9Sjo OH, Merok MA, Svindland A, et al. Prognostic impact of lymphnode harvest and lymph node ratio in patients with colon cancer. DisColon Rectum, 2012, 55(3): 307-315.
  • 10Rosenberg R, Friederichs J, Schuster T, et al. Prognosis of patients withcolorectal cancer is associated with lymph node ratio: a single-centeranalysis of 3, 026 patients over a 25-year time period. Ann Surg,2008, 248(6): 968-978.

二级参考文献25

  • 1Siegel R, Naishadham D,Jemal A, et al. Cancer statistics [J]. JAMA,2013,310(9) :982.
  • 2Kolligs FT. Screening for colorectal cancer. Current evi- dence and novel developments [J]. Radiologe, 2012, 52 (6) :504-510.
  • 3Bertelsen CA, Bols B, Ingeholm P, et al. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision? [J]. Color- ectal Dis, 2011,13(10) : 1123-1129.
  • 4Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surger- y alone for resectable liver metastases from eoloreetal cancer (EORTC Intergroup trial 40983) : a randomised controlled trial[J]. Lancet, 2008,371 ( 9617 ) : 1007-1016.
  • 5Bartlett DL, Berlin J, Lauwers GY, et al. Chemotherapy and regional therapy of hepatic colorectal metastases: ex- pert consensus statement[J]. Ann Surg Oncol, 2006,13 (10) :1284-1292.
  • 6Adair RA,Young AL,Cockbain AJ,et al. Repeat hepatic resection for colorectal liver metastases [J]. Br J Surg, 2012,99(9) :1278-1283.
  • 7Millo P, Rispoli C, Rocco N, et al. Laparoscopic surgery for colon cancer[J]. Health News,2002,8(9) :8.
  • 8Fleshman J, Sargent DJ, Green E, et al. Laparoscopic co- lectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study Group trial[J]. Ann Surg, 2007,246 (4) : 655-662.
  • 9Mirza MS, Longman RJ, Farrokhyar F, et al. Long-term outcomes for laparoscopie versus open resection of non- metastatic colorectal cancer[J]. J Laparoendosc Adv Surg Tech A,2008,18(5) :679-685.
  • 10National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, colorectal cancer(NCCN guidelines) [M]. Philadelphia, 2011 : 20-21.

共引文献46

同被引文献54

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部